Lenalidomide in myelodysplastic syndrome and multiple myeloma

Drugs

Volumn 67, Issue 13, 2007, Pages 1869-1881

  Shah, Sachin R ^a   Tran, Thu M ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; AZACITIDINE; BORTEZOMIB; CLARITHROMYCIN; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE; WARFARIN;

ADD ON THERAPY; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BINDING; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ERYTHROCYTE TRANSFUSION; FATIGUE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; PNEUMONIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SEDATION; SIDE EFFECT; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 34548370723     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767130-00005     Document Type: Review

References (58)

1. Argiles JM, Carbo N, Lopez-Soriano FJ. Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? Med Hypotheses 1998; 50: 313-8
2. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005; 7: E14-9
3. Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol 2005; 32 Suppl. 5: S24-30
4. Lenz W. Perthes-like changes in thalidomide children. Lancet 1967; II: 562
5. Rajkumar SV. Current status of thalidomide in the treatment of cancer. Oncology 2001; 15: 867-74
6. Teo SK, Resztak KE, Scheffler MA, et al. Thalidomide in the treatment of leprosy. Microbes Infect 2002; 4: 1193-202
7. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965; 6: 303-6
8. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-65
9. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71
10. Furman RR, Leonard JP, Allen SL, et al. Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL [abstract]. Proc Am Soc Clin Oncol 2005; 23: 6640
11. Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc 2004; 79: 883-9
12. Dimopoulos MA, Tsatalas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003; 30: 265-9
13. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-6
14. Celgene Corporation. Thalidomid® (thalidomide) package insert. Warren (NJ): Celgene Corporation, 2006
15. Celgene Corporation. Revlimid® (lenalidomide) package insert. Summit (NJ): Celgene Corporation, 2006
16. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-7
17. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004; 22: 3212-4
18. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am Soc Hematol Educ Program) 2005; 2005 (1): 161-6
19. List AF. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin Oncol 2005; 32 Suppl. 5: S31-5
20. Wu A, List A, Lush R, et al. A pharmacokinetic and pharmacodynamic study of oral lenalidomide in patients with low or intermediate-risk myelodysplastic syndromes [abstract]. Blood 2006; 108: 4854
21. National Comprehensive Cancer Network. NCCN guidelines v.4.2006: myelodysplastic syndrome [online]. Available from URL: http://www.nccn.org [Accessed 2006 Sep 13]
22. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Eng J Med 2005; 352: 549-57
23. List AF, Dewald G, Bennett A, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-65
24. Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005; 84: 569-71
25. List A, Dewald G, Bennett J, et al. Clinical benefit from 2 phase II trials evaluating lenalidomide (Revlimid) in lower-risk myelodysplastic syndrome patients with or without del 5q cytogenetic abnormalities [abstract]. European Hematology Association 11th Congress Proceedings; 2006 Jun 15-18; Amsterdam, 1032
26. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the CALGB. J Clin Oncol 2002; 20: 2429-40
27. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-803
28. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304-9
29. Molldrem J, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndromes. Br J Haematol 1997; 99: 699-705
30. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
31. National Cancer Institute. Cancer topics: multiple myeloma [online]. Available from URL: http://www.cancer.gov/cancer-topics/pdq/treatment/myeloma/ healthprofessional [Accessed 2006 Jun 8]
32. Child JA, Morgan GJ, Davies FE. Medical Research Council Adult Leukemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Eng J Med 2003; 348: 1875
33. Facon T, Mary J, Harousseau J, et al. Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]. Proc Am Soc Clin Oncol 2006; 24: 1
34. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-36
35. National Comprehensive Cancer Network. NCCN guidelines v.1.2006: multiple myeloma [online]. Available from URL: http://www.nccn.org [Accessed 2006 May 1]
36. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-31
37. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98
38. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 358: 2609-17
39. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-9
40. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-23
41. Dimopoulos MA, Spencer A, Attal M, et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma: results of a phase 3 study (MM-010) [abstract]. Am Soc of Hem 2005; 106: 6
42. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract]. Proc Am Soc Clin Oncol 2006; 24: 7521
43. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-64
44. Wang M, Knight R, Dimopoulos M. Comparison of lenalidomide in combination with dexamethasone to dexamethasone alone in patients who have received prior thalidomide in relapsed or refractory multiple myeloma [abstract]. Proc Am Soc Clin Oncol 2006; 24: 7522
45. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-3
46. Nievsvizky R, Jayablan DS, Zafar F, et al. Lenalidomide induced myelosuppression is potentially associated with renal dysfunction in treatment naïve myeloma (MM) patients receiving BiRD (Biaxin/Revlimid/Dexamethasone) combination therapy (Rx) [abstract no. 3549]. American Society of Hematology Annual Meeting Proceedings; 2006 Dec 9-12; Orlando (FL)
47. Roy V, Leif BP, Jacob A, et al. Melphalan (M), prednisone (P), and lenalidomide (R) combination (MPR) for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation [abstract no. 3558]. American Society of Hematology Annual Meeting Proceedings; 2006 Dec 9-12; Orlando (FL)
48. Richardson PG, Jagannath S, Avigan DE, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma: final results of multicenter phase 1 trial [abstract no. 405]. American Society of Hematology Annual Meeting Proceedings; 2006 Dec 9-12; Orlando (FL)
49. Knop S, Gerecke C, Topp MS, et al. Lenalidomide (Revlimid), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma: first results of German Multicenter phase I/II trial [abstract]. Blood 2006; 108: 408
50. Southwest Oncology Group. Clinical trials: open protocols [online]. Available from URL: http://www.swog.org [Accessed 2006 Jun 2]
51. Rajkumar SV, Blood E. Lenalidomide and venous thromboembolism in multiple myeloma. N Engl J Med 2006; 354: 2080
52. Eastern Cooperative Oncology Group. General information: clinical trial [online]. Available from URL: http://www.ecog.org [Accessed 2006 Jun 2]
53. Clinical Trials. Lenalidomide [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2006 Jun 2]
54. Rajkumar SV, Jacobus S, Callander N, et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 2006; 108: 799
55. Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thromboembolism in multiple myeloma. N Engl J Med 2006; 354: 2079-80
56. Niesvizky R, Spencer A, Wang M, et al. Increased risk of thrombosis with lenalidomide in combination with dexamethasone and erythropoietin [abstract]. Proc Am Soc of Clin Oncol 2006; 24: 7506
57. Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108: 403
58. Weber D, Wang M, Chen C, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma(mm): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function [abstract no. 3547]. American Society of Hematology Annual Meeting Proceedings; 2006 Dec 9-12; Orlando (FL)